Rubius Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Rubius Therapeutics

09/08/2022 14:32

* Rubius Therapeutics Inc  RUBY.OQ  reported a quarterly
adjusted
loss of 49 cents​​ per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 53 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Rubius Therapeutics Inc's reported EPS for the quarter was
a
loss of 49 cents​.
    * The mean earnings estimate of analysts had risen by
about 8% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Rubius Therapeutics Inc shares had fallen by 6.8% this
quarter and lost 91.8% so far this year.
    * The company reported a quarterly loss of $44.24 million.
    * Wall Street's median 12-month price target for Rubius
Therapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 9
at 01:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.53          -0.49          Beat
 Mar. 31 2022      -0.58          -0.58          Met
 Dec. 31 2021      -0.59          -0.61          Missed
 Sep. 30 2021      -0.57          -0.55          Beat